Aperam

A substantial increase in our TP in the new “EU context”.

09/02/26 -"Our target price goes up substantially on the back of our earnings revision, particularly as of FY27, where the new EU measures (CBAM and tariffs) will be in force over the full year, as well as ..."

PDF page sample
Pages
67
Language
English
Published on
09/02/26
Download
You may also be interested by these reports :
09/02/26
Our target price goes up substantially on the back of our earnings revision, particularly as of FY27, where the new EU measures (CBAM and tariffs) ...
09/02/26
Our target price goes up substantially on the back of our earnings revision as well as long-term growth estimates, based on the new European measures ...
06/02/26
Aperam reported satisfactory results for FY25, although Q4 slightly underperformed expectations. More significantly, the anticipated impact of the ...
05/02/26
Sadly, Rio-Glencore have abandoned their merger talks. It is believed that Rio seeking the all-important Chairman and CEO roles in the combined firm ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO